A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

Overview of attention for article published in Breast Cancer Research and Treatment, December 2011

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (74th percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 1 X user

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 51 Dimensions

Readers on

mendeley: 90 Mendeley

Summary X Wikipedia Dimensions citations

So far, Altmetric has seen 1 X post from an account with 43 followers.

VALUE BASED PRICING- #Bevacizumab in combination with #paclitaxel analysis for Metastatic #BreastCancer: http://t.co/Tw1AEjjd1M |#QALY

Reply Repost Favourite